Clinical Trial Update: Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis [Phase 4]

View source ↗

Summary

Open-label Phase 4 study assessing pimavanserin on activities of daily living in Parkinson disease psychosis. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease Psychosis

Drugs mentioned

• Pimavanserin (pimavanserin)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Parkinson Disease Psychosis | Phase 4 | Status: COMPLETED | Results posted: 2025-01-14